Some news items you might have missed: • Pink News: Actor Kal Penn (above) will star in a comedy series about coming out in your 40s, just weeks after he came out as gay himself. Continue reading “News Round-Up: November 26, 2021”
Merck Will License Merck COVID-19 Pill Royalty-Free
Pharmaceutical company Merck & Co. has announced it will allow drugmakers around the world to produce its potentially lifesaving antiviral pill for treatment of COVID-19 without paying royalties as long as COVID-19 is considered a global health threat. Continue reading “Merck Will License Merck COVID-19 Pill Royalty-Free”
Experimental Pill To Treat COVID-19 Cuts Risk Of Hospitalizations & Death In Half
An experimental pill developed by Merck to treat COVID-19 has done so well in late-stage clinical trials – reducing risk of hospitalization and death by nearly half – that an independent board of experts recommended stopping the trial early. Continue reading “Experimental Pill To Treat COVID-19 Cuts Risk Of Hospitalizations & Death In Half”
Study: 28% Of Millennials Avoid Hugging HIV+ People
The results of a new study by pharmaceutical giant Merck and the Prevention Access Campaign finds many young people today know little about HIV. Survey findings revealed the 1,596 respondents – who either identified as Generation Z (18-22) or millennials (23-36) – are woefully uninformed about HIV and its transmission. From the study: • 41% of Gen Z respondents were either somewhat informed or not at all informed about HIV, compared to 23% of millennials • While 67% said they were most concerned about HIV compared to other STIs, 54% did not report using condoms or PrEP. • 28% of HIV-negative millennials said they have avoided hugging or interacting with HIV-positive people, even though the virus cannot be transmitted through casual contact • 76% of those living with HIV said they were hesitant to share their status for fear of being judged • 90% of those living with HIV said they avoided sharing their status for fear of losing friends or family Bruce Richman, executive director of the Prevention Access Campaign said in a statement, ”Despite scientific advances and decades of HIV advocacy and education, the findings highlight a disturbing trend: young adults overwhelmingly are not being informed effectively about the basics of HIV.” “These findings are a call to action that the crisis in the United States is far from over,” added Richman. “It’s time to elevate a real conversation about HIV and sexual health among America’s young people, and roll out innovative and engaging initiatives to educate and fight HIV stigma.” As a result of the survey, Merck and Prevention Access Campaign have launched a new project called Owning HIV: Young Adults and the Fight Ahead aimed at educating young Americans about HIV and elevating the urgency around the issue.
Merck Gets FDA Approval On 2 New HIV Meds
Pharmaceutical drug giant Merck has obtained approval from the Food and Drug Administration (FDA) for two new medications to address HIV.
Pifeltro (doravirine) is a new non-nucleoside reverse transcriptase inhibitor (NNRTI). That medication is paired in a three-drug single tablet dose to be marketed as Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate).
Both are indicated for treating HIV-1 in adults with no prior anti-retroviral treatment.
The approval for the once-a-day pills come after two double-blind, active-controlled phase 3 trials showed positive results.
In a trial called “Drive-Ahead,” 728 patients were treated with either Delstrigo or Gilead’s Atripla for 48 weeks.
At the end of the study, viral suppression rates were similar with Delstrigo reaching 84% and Atripla achieving 81% suppression.
In addition to edging Atripla on viral suppression, Delstrigo patients saw better results regarding LDL cholesterol and non-HDL cholesterol.
The Delstrigo group also experienced lower incidence of neuropsychiatric adverse issues like sleep problems, dizziness and being able to concentrate more clearly.
While there is currently no cure for HIV/AIDS, the Centers for Disease Control have previously announced that when HIV+ folks stay on their prescribed medications on a daily basis, not only are viral loads lowered to ‘undetectable,’ but ‘undetectable’ means the virus is untransmittable.